These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32416364)

  • 21. Anticoagulation Control in Patients With Nonvalvular Atrial Fibrillation Attended at Primary Care Centers in Spain: The PAULA Study.
    Barrios V; Escobar C; Prieto L; Osorio G; Polo J; Lobos JM; Vargas D; García N
    Rev Esp Cardiol (Engl Ed); 2015 Sep; 68(9):769-76. PubMed ID: 26169326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II.
    Oh S; Kim JS; Oh YS; Shin DG; Pak HN; Hwang GS; Choi KJ; Kim JB; Lee MY; Park HW; Kim DK; Jin ES; Park J; Oh IY; Shin DH; Park HS; Kim JH; Kim NH; Ahn MS; Seo BJ; Kim YJ; Kang S; Lee J; Kim YH
    J Korean Med Sci; 2018 Dec; 33(49):e323. PubMed ID: 30505257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of renal function on anticoagulation control in patients with non-valvular atrial fibrillation taking vitamin K antagonists.
    Lobos-Bejarano JM; Castellanos Rodríguez A; Barrios V; Escobar C; Polo-García J; Del Castillo-Rodríguez JC; Vargas-Ortega D; Lopez-Pineda A; Prieto-Valiente L; Lip GYH;
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28722795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
    Pokorney SD; Simon DN; Thomas L; Fonarow GC; Kowey PR; Chang P; Singer DE; Ansell J; Blanco RG; Gersh B; Mahaffey KW; Hylek EM; Go AS; Piccini JP; Peterson ED;
    Am Heart J; 2015 Jul; 170(1):141-8, 148.e1. PubMed ID: 26093875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is the time in therapeutic range using the ratio of tests equivalent to the Rosendaal method?
    Caldeira D; Cruz I; Morgado G; Stuart B; Gomes AC; Martins C; João I; Pereira H
    Blood Coagul Fibrinolysis; 2015 Dec; 26(8):972-6. PubMed ID: 26083988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control.
    Bonde AN; Staerk L; Lee CJ; Vinding NE; Bang CN; Torp-Pedersen C; Gislason G; Lip GYH; Olesen JB
    J Am Coll Cardiol; 2018 Sep; 72(12):1357-1365. PubMed ID: 30213328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol.
    Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Marín F; Lip GYH
    Clin Ther; 2018 Jan; 40(1):114-122. PubMed ID: 29275065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective 'Real-world' Inception Cohort Study.
    Roldán V; Cancio S; Gálvez J; Valdés M; Vicente V; Marín F; Lip GY
    Am J Med; 2015 Nov; 128(11):1237-43. PubMed ID: 26087049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists.
    Fitzmaurice DA; Accetta G; Haas S; Kayani G; Lucas Luciardi H; Misselwitz F; Pieper K; Ten Cate H; Turpie AG; Kakkar AK;
    Br J Haematol; 2016 Aug; 174(4):610-23. PubMed ID: 27071942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SAMe-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events.
    Pivatto Junior F; Scheffel RS; Ries L; Wolkind RR; Marobin R; Barkan SS; Amon LC; Biolo A
    Arq Bras Cardiol; 2017 Apr; 108(4):290-296. PubMed ID: 28538758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
    Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
    Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study).
    Hellyer JA; Azarbal F; Than CT; Fan J; Schmitt SK; Yang F; Frayne SM; Phibbs CS; Yong C; Heidenreich PA; Turakhia MP
    Am J Cardiol; 2017 Jan; 119(2):268-274. PubMed ID: 27836133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists.
    Ruiz-Ortiz M; Bertomeu V; Cequier Á; Marín F; Anguita M
    Thromb Haemost; 2015 Oct; 114(4):695-701. PubMed ID: 26054407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with atrial fibrillation and obstructive sleep apnea.
    Szymanski FM; Lip GY; Filipiak KJ; Platek AE; Karpinski G
    Int J Cardiol; 2016 Feb; 204():200-5. PubMed ID: 26670173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation.
    Pastori D; Pignatelli P; Saliola M; Carnevale R; Vicario T; Del Ben M; Cangemi R; Barillà F; Lip GY; Violi F
    Int J Cardiol; 2015 Dec; 201():513-6. PubMed ID: 26318513
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.
    Gallego P; Roldan V; Marín F; Romera M; Valdés M; Vicente V; Lip GY
    Thromb Haemost; 2013 Dec; 110(6):1189-98. PubMed ID: 24096615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.